Skip to main content

Table 3 Prognostic factors by univariate and multivariate analyses

From: Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

  OS LFFS DFFS OS LFFS DFFS
Prognostic factors p HR (95.0% CI) p HR (95.0% CI) p HR (95.0% CI) p HR (95.0% CI) p HR (95.0% CI) p HR (95.0% CI)
Gender 0.38 0.817 (0.521–1.281) 0.37 0.75 (0.406–1.402) 0.96 0.984 (0.508–1.907)       
Age 0.70 1.005 (0.980–1.031) 0.03 0.97 (0.934–0.997) 0.03 1.049 (1.005–1.094)       
ECOG 0.60 0.904 (0.622–1.313) 0.51 0.85 (0.521–1.385) 0.68 1.133 (0.627–2.050)       
Tumor location 0.05 0.814 (0.661–1.001) 0.01 0.69 (0.518–0.905) 0.64 0.927 (0.671–1.279)       
Clinical T stage 0.19 1.191 (0.919–1.543) 0.98 1.00 (0.714–1.414) 0.47 1.158 (0.775–1.730)       
Clinical N stage < 0.01 2.996(2.037–4.408) 0.00 2.68 (1.671–4.289) < 0.01 2.495 (1.440–4.324) < 0.01 2.465 (1.612–3.769) < 0.01 2.293 (1.384–3.798) < 0.01 2.418 (1.345–4.346)
Clinical M stage < 0.01 2.142(1.463–3.136) 0.02 1.83 (1.094–3.046) < 0.01 2.463 (1.391–4.362) < 0.01 1.856 (1.268–2.716)    < 0.01 2.424 (1.358–4.238)
Clinical TNM stage < 0.01 1.402(1.181–1.665) 0.03 1.29 (1.023–1.616) < 0.01 1.487 (1.133–1.953)       
Cycles of CC 0.95 0.990(0.719–1.365) 0.83 1.05 (0.682–1.608) 0.20 0.725 (0.442–1.187)       
Regimen of CC 0.07 0.646(0.405–1.030) 0.87 0.94 (0.485–1.481) 0.63 1.235 (0.529–2.884)       
Dose of GTV 0.51 1.000(0.999–1.000) 0.06 1.00 (0.999–1.000) 0.81 1.000 (0.999–1.001)       
Dose of CTV 0.18 1.001(0.999–1.003) 0.78 1.00 (0.999–1.002) 0.70 1.000 (0.998–1.002)       
Tumor response to CRT < 0.01 1.691(1.389–2.060) < 0.01 1.71 (1.315–2.228) 0.44 1.127 (0.834–1.524) < 0.01 1.548 (1.262–1.899) < 0.01 1.532 (1.162–2.021)   
AC 0.74 0.971(0.819–1.152) 0.88 1.02 (0.809–1.281) 0.21 0.841 (0.643–1.100)       
  1. CC concurrent chemotherapy; GTV gross tumor volume; CTV clinical target volume; CRT concurrent chemoradiotherapy; AC adjuvant chemotherapy